OtherREVIEW ARTICLE
Whole-Brain N-Acetylaspartate as a Surrogate Marker of Neuronal Damage in Diffuse Neurologic Disorders
D.J. Rigotti, M. Inglese and O. Gonen
American Journal of Neuroradiology November 2007, 28 (10) 1843-1849; DOI: https://doi.org/10.3174/ajnr.A0774
D.J. Rigotti
M. Inglese
References
- ↵McFarland H. The lesion in multiple sclerosis: clinical, pathological, and magnetic resonance imaging considerations. J Neurol Neurosurg Psychiatry 1998;64S1:S26–S30
- Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393–99
- ↵Bitsch A, Bruhn H, Vougioukas V, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999;20:1619–27
- ↵Miller BL. A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 1991;4:47–52
- ↵Lin A, Ross BD, Harris K, et al. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 12005;2:197–214
- ↵Tallan HH, Moore S, Stein WH. N-acetyl-L-aspartic acid in brain. J Biol Chem 1956;219:257–64
- ↵Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991;45:37–45
- Jenkins BG, Klivenyi P, Kustermann E, et al. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem 2000;74:2108–19
- ↵Moffett JR, Namboodiri MA, Cangro CB, et al. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991;2:131–34
- ↵Baslow MH, Resnik TR. Canavan disease: analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms. J Mol Neurosci 1997;9:109–25
- ↵Danielsen EA, Ross B. Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases. New York: Marcel Dekker;1999 .
- ↵
- ↵Bjartmar C, Battistuta J, Terada N, et al. N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. Ann Neurol 2002;51:51–58
- ↵Bjartmar C, Kidd G, Mork S, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000;48:893–901
- ↵Goldstein FB. Biosynthesis of N-acetyl-L-aspartic acid. Biochim Biophys Acta 1959;33:583–84
- ↵
- ↵Chakraborty G, Mekala P, Yahya D, et al. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J Neurochem 2001;78:736–45
- ↵Madhavarao CN, Chinopoulos C, Chandrasekaran K, et al. Characterization of the N-acetylaspartate biosynthetic enzyme from rat brain. J Neurochem 2003;86:824–35
- ↵
- ↵Kreis R, Ernst T, Ross BD. Absolute quantitation of water and metabolites in the human brain. II. metabolite concentrations. J Magn Reson Series B 1993;102:9–19
- Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989;13:23–31
- Arnold DL, de Stefano N, Matthews PM, et al. N-acetylaspartate: usefulness as an indicator of viable neuronal tissue. Ann Neurol 2001;50:823–25
- ↵Baslow MH. Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling. J Neurochem 2000;75:453–59
- ↵Brooks WM, Friedman SD, Stidley CA. Reproducibility of 1H-MRS in vivo. Magn Reson Med 1999;41:193–97
- Marshall I, Wardlaw J, Cannon J, et al. Reproducibility of metabolite peak areas in 1H MRS of brain. Magn Reson Imaging 1996;14:281–92
- ↵Bokde AL, Teipel SJ, Zebuhr Y, et al. A new rapid landmark-based regional MRI segmentation method of the brain. J Neurol Sci 2002;194:35–40
- ↵Inglese M, Ge Y, Filippi M, et al. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 2004;21:1825–29
- ↵De Stefano N, Narayanan S, Francis SJ, et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 2002;59:1565–71
- ↵
- ↵Gonen O, Viswanathan AK, Catalaa I, et al. Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med 1998;40:684–89
- ↵Udupa JK, Odhner D, Samarasekera S. 3DVIEWNIX: an open, transportable, multdimensional, multimodality, multiparametric imaging software system. Proc SPIE 1994;2164:58–73
- ↵De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529–39
- ↵Ashburner J, Hutton C, Frackowiak R, et al. Identifying global anatomical differences: deformation-based morphometry. Hum Brain Mapp 1998;6:348–57
- ↵Smith SM, De Stefano N, Jenkinson M, et al. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001;25:466–75
- ↵Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89
- ↵Smith SM, Rao A, De Stefano N, et al. Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: cross-validation of BSI, SIENA and SIENAX. Neuroimage 2007;36:1200–06. Epub 2007 Apr 27
- ↵Gonen O, Grossman RI. The accuracy of whole brain N-acetylaspartate quantification. Magn Reson Imaging 2000;18:1255–58
- ↵Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433–37
- ↵Benedetti B, Rigotti DJ, Liu S, et al. Reproducibility of the whole-brain N-acetylaspartate level across institutions, MR scanners, and field strengths. AJNR Am J Neuroradiol 2007;28:72–75
- ↵Rigotti DJ, Inglese M, Babb JS, et al. Serial whole-brain N-acetylaspartate concentration in healthy young adults. AJNR Am J Neuroradiol. 2007;28:1650–51
- ↵
- ↵Scahill RI, Frost C, Jenkins R, et al. A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 2003;60:989–94
- ↵Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221–31
- ↵Sayao AL, Devonshire V, Tremlett H. Longitudinal follow-up of “benign” multiple sclerosis at 20 years. Neurology 2007;68:496–500
- ↵Montalban X. Primary progressive multiple sclerosis. Curr Opin Neurol 2005;18:261–66
- ↵Cree B. Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 2006;12:171–78
- ↵Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther 2006;28:461–74
- ↵Miller DH, Thompson AJ, Filippi M. Magnetic resonance studies of abnormalities in the normal-appearing white matter and gray matter in multiple sclerosis. J Neurol 2003;250:1407–19
- ↵Gonen O, Catalaa I, Babb JS, et al. Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000;54:15–19
- ↵Rovaris M, Gallo A, Falini A, et al. Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. Arch Neurol 2005;62:898–902
- ↵Ge Y, Gonen O, Inglese M, et al. Neuronal cell injury precedes brain atrophy in multiple sclerosis. Neurology 2004;62:624–27
- ↵Lumsden C. The clinical immunology of multiple sclerosis. In: BG Vinken PJ, ed. Handbook of Clinical Neurology. Vol.9 . North-Holland, Amsterdam: Elsevier;1970 :217–309
- ↵Gonen O, Moriarty DM, Li BS, et al. Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations. Radiology 2002;225:261–68
- ↵Gonen O, Oberndorfer TA, Inglese M, et al. Reproducibility of 3 whole-brain N-acetylaspartate decline cohorts in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2007;28:267–71
- ↵Weinshenker BG. Natural history of multiple-sclerosis. Ann Neurol 1994;36:S6–S11
- ↵Rovaris M, Gambini A, Gallo A, et al. Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology 2005;65:1626–30
- ↵Patel SH, Inglese M, Glosser G, et al. Whole-brain N-acetylaspartate level and cognitive performance in HIV infection. AJNR Am J Neuroradiol 2003;24:1587–91
- ↵Medana IM, Esiri MM. Axonal damage: a key predictor of outcome in human CNS diseases. Brain 2003;126:515–30
- ↵Cohen BA, Inglese M, Rusinek H, et al. Proton MR spectroscopy and MRI-volumetry in mild traumatic brain injury. AJNR Am J Neuroradiol 2007;28:907–13
- ↵DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114–23
- ↵Surawicz TS, McCarthy BJ, Kupelian V, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neuro Oncol 1999;1:14–25
- ↵Lunsford LD, Martinez AJ, Latchaw RE. Magnetic resonance imaging does not define tumor boundaries. Acta Radiol Suppl 1986;369:154–56
- ↵Cohen BA, Knopp EA, Rusinek H, et al. Assessing global invasion of newly diagnosed glial tumors with whole-brain proton MR spectroscopy. AJNR Am J Neuroradiol 2005;26:2170–77
- ↵Inglese M, Brown S, Johnson G, et al. Whole-brain N-acetylaspartate spectroscopy and diffusion tensor imaging in patients with newly diagnosed gliomas: a preliminary study. AJNR Am J Neuroradiol 2006;27:2137–40
- ↵Curnes JT. MR imaging of peripheral intracranial neoplasms: extraaxial vs intraaxial masses. J Comput Assist Tomogr 1987;11:932–37
- ↵Cohen BA, Knopp EA, Rusinek H, et al. Brain compression without global neuronal loss in meningiomas: whole-brain proton MR spectroscopy report of 2 cases. AJNR Am J Neuroradiol 2005;26:2178–82
- ↵Aupérin A, Arriagada R, PIgnon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476–84
- ↵Movsas B, Li BS, Babb JS, et al. Quantifying radiation therapy-induced brain injury with whole-brain proton MR spectroscopy: initial observations. Radiology 2001;221:327–31
In this issue
Advertisement
Whole-Brain N-Acetylaspartate as a Surrogate Marker of Neuronal Damage in Diffuse Neurologic Disorders
D.J. Rigotti, M. Inglese, O. Gonen
American Journal of Neuroradiology Nov 2007, 28 (10) 1843-1849; DOI: 10.3174/ajnr.A0774
Jump to section
Related Articles
- No related articles found.
Cited By...
- Longitudinal Evaluation of Magnetic Resonance Spectroscopy Metabolites as Biomarkers in Huntingtons Disease
- Neuroimaging of Sports Concussions
- Whole-Brain N-Acetylaspartate Concentration Is Preserved during Mild Hypercapnia Challenge
- Alzheimer Disease: Focus on Computed Tomography
- Metabolic Changes in Patients with Aneurysmal Subarachnoid Hemorrhage Apart from Perfusion Deficits: Neuronal Mitochondrial Injury?
- Two-year serial whole-brain N-acetyl-L-aspartate in patients with relapsing-remitting multiple sclerosis
- Longitudinal Whole-Brain N-Acetylaspartate Concentration in Healthy Adults
- Diffuse White Matter Damage Is Absent in Neuromyelitis Optica
- Vitamin A Deficiency in Rats Induces Anatomic and Metabolic Changes Comparable with Those of Neurodegenerative Disorders
- Changes in NAA and lactate following ischemic stroke: A serial MR spectroscopic imaging study
This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.
- Gülin Öz, Jeffry R. Alger, Peter B. Barker, Robert Bartha, Alberto Bizzi, Chris Boesch, Patrick J. Bolan, Kevin M. Brindle, Cristina Cudalbu, Alp Dinçer, Ulrike Dydak, Uzay E. Emir, Jens Frahm, Ramón Gilberto González, Stephan Gruber, Rolf Gruetter, Rakesh K. Gupta, Arend Heerschap, Anke Henning, Hoby P. Hetherington, Franklyn A. Howe, Petra S. Hüppi, Ralph E. Hurd, Kejal Kantarci, Dennis W. J. Klomp, Roland Kreis, Marijn J. Kruiskamp, Martin O. Leach, Alexander P. Lin, Peter R. Luijten, Małgorzata Marjańska, Andrew A. Maudsley, Dieter J. Meyerhoff, Carolyn E. Mountford, Sarah J. Nelson, M. Necmettin Pamir, Jullie W. Pan, Andrew C. Peet, Harish Poptani, Stefan Posse, Petra J. W. Pouwels, Eva-Maria Ratai, Brian D. Ross, Tom W. J. Scheenen, Christian Schuster, Ian C. P. Smith, Brian J. Soher, Ivan Tkáč, Daniel B. Vigneron, Risto A. KauppinenRadiology 2014 270 3
- R. Vagnozzi, S. Signoretti, L. Cristofori, F. Alessandrini, R. Floris, E. Isgro, A. Ria, S. Marziale, G. Zoccatelli, B. Tavazzi, F. Del Bolgia, R. Sorge, S. P. Broglio, T. K. McIntosh, G. LazzarinoBrain 2010 133 11
- Rosalind Arden, Robert S. Chavez, Rachael Grazioplene, Rex E. JungBehavioural Brain Research 2010 214 2
- Ofer Pasternak, Marek Kubicki, Martha E. ShentonSchizophrenia Research 2016 173 3
- Balasrinivasa R. Sajja, Jerry S. Wolinsky, Ponnada A. NarayanaNeuroimaging Clinics of North America 2009 19 1
- S. Muñoz Maniega, V. Cvoro, F. M. Chappell, P. A. Armitage, I. Marshall, M. E. Bastin, J. M. WardlawNeurology 2008 71 24
- Jonathan J. S. Rickard, Valentina Di-Pietro, David J. Smith, David J. Davies, Antonio Belli, Pola Goldberg OppenheimerNature Biomedical Engineering 2020 4 6
- Michelle M. Kim, Abhijit Parolia, Mark P. Dunphy, Sriram VennetiNature Reviews Clinical Oncology 2016 13 12
- Violaine K. Harris, Saud A. SadiqMolecular Diagnosis & Therapy 2009 13 4
- Roberto Vagnozzi, Stefano Signoretti, Roberto Floris, Simone Marziali, Massimo Manara, Angela M. Amorini, Antonio Belli, Valentina Di Pietro, Serafina D'Urso, Francesco S. Pastore, Giuseppe Lazzarino, Barbara TavazziJournal of Head Trauma Rehabilitation 2013 28 4
More in this TOC Section
Similar Articles
Advertisement